QR Group Explica as Mudanças na RDC 954/2024 e Seu Impacto no Registro de Medicamentos
New ANVISA resolution updates criteria for simplified registration and brings greater clarity to the regulatory process With official publication in April and expected to come into force in October 2024, RDC No. 954/2024 brings an important update to the drug registration process with ANVISA. The new rule repeals RDC No. 199/2006 and redefines the criteria […]
RDC 954/2024 Updates Simplified Medication Registration
QR Group analyzes the impacts of ANVISA’s new rule and guides companies on how to adapt to changes in the regularization process ANVISA published RDC No. 954/2024, which updates the criteria and procedures for the simplified registration of medicines. The new rule repeals the old RDC No. 199/2006 and comes into force as of October […]
RDC 954/2024: Updates to the Simplified Drug Registration Procedure
Key Changes and Impacts for Drug Manufacturers The recent update of RDC 954/2024 brought significant changes to the simplified procedure for registering medicines in Brazil. In an exclusive event held by ANVISA on March 13, experts discussed the main guidelines and their impacts on the pharmaceutical sector. QR Group has closely followed the news to […]
QR Group Explains the Changes in RDC 954/2024 and Its Impact on Drug Registration
Understand How the Changes in RDC 954/2024 Impact Drug Registration and How QR Group Assists International Manufacturers With the entry into force of RDC 954/2024, the drug registration process undergoes significant changes. The rule revises and simplifies the regulatory procedure, promoting greater speed in the registration, post-registration and renewal processes. QR Group, a specialist in […]
